Chicago-Members of the Society of University Urologists have agreed tocreate a new group consisting of U.S.-based urology program directors. Thenew, yet-unnamed organization will have both fund-raising and task-orientedresponsibilities, including assisting programs with new competency requirements,said Robert Flanigan, MD, professor and chairman of the department of urologyat Loyola University, Maywood, IL, who will serve as president of the group.Other officers will include Marc Cohen, MD, of the Medical College ofGeorgia in Augusta; and Michael Koch, MD, of Indiana University, Indianapolis.
The phase 1/2 CELC-G-201 study found preliminary antitumor activity and manageable toxicity with gedatolisib plus darolutamide in metastatic castration-resistant prostate cancer.
Kim Chi, MD, FRCPC, discusses the rationale and design of the phase 3 KLK2-comPAS trial evaluating pasritamig alone and in combination with JNJ-9401 in patients with mCRPC.
Engy Habashy, MD, discusses key takeaways from the 2025 AUA GSM guideline, including the role of androgens and hormonal therapies in managing genitourinary syndrome of menopause.
Chad R. Ritch, MD, MBA, FACS, discusses how PSMA-PET informs staging, treatment planning, recurrence workup, and the interpretation of equivocal findings.
Michael S. Cookson, MD, MMHC, FACS, discusses how Anktiva’s expanded FDA approval may broaden bladder-preserving treatment options for BCG-unresponsive papillary-only NMIBC.